

Benralizumab (Fasenra) Induction Followed by Maintenance Every 8 Weeks

benralizumab (FASENRA) Induction 30 mg every 4 weeks x3 doses followed by maintenance, 30 mg every 8 weeks, starting day 112 (Week 16)

Protocol Types

Infusion Treatment 1, Infusion Treatment 2, Infusion Treatment 3, Infusion Treatment 4

Patient name: _____ DOB: _____

Please include: ☐ Patient face sheet ☐ Insurance authorization (if other than Medicaid or non-Advantage Medicare)

Diagnosis: _____

Review: Every 358 days

Orders

	Interval	Defer Until	Duration
Provider Communication			
☒ Provider communication	Every visit		Until discontinued
Until discontinued Starting when released Until Specified			
Benralizumab is not indicated for the treatment of acute asthma symptoms or acute exacerbations.			
Nursing Orders			
☒ Nursing communication	Every visit		Until discontinued
Until discontinued Starting when released Until Specified			
Following infusion, monitor patient for signs and symptoms of reaction for 30 minutes.			
Therapeutic Medications			
☒ benralizumab (Fasenra) injection 30 mg	Every 28 days		3 treatments
30 mg, subcutaneous, Once, Starting when released			
Administer in the thigh, upper arm, or abdomen at least 2 inches from belly button and 1 inch from last injection site. Benralizumab syringe may contain a small air bubble. Do not expel the air bubble prior to administration.			
Do not shake. Remove from fridge and allow to sit at room temperature for 30 minutes prior to administering.			
☒ benralizumab (Fasenra) injection 30 mg	Every 56 days	S+112	Until discontinued
30 mg, subcutaneous, Once, Starting when released			
Administer in the thigh, upper arm, or abdomen at least 2 inches from belly button and 1 inch from last injection site. Benralizumab syringe may contain a small air bubble. Do not expel the air bubble prior to administration.			
Do not shake. Remove from fridge and allow to sit at room temperature for 30 minutes prior to administering.			
Emergency Medications			
☒ Nursing communication	PRN		Until discontinued
STAT, Until discontinued Starting when released Until Specified			
If hypersensitivity reaction occurs, stop infusion IMMEDIATELY and CALL provider.			
☒ Vital Signs	PRN		Until discontinued
STAT, Every 15 min Starting when released			
If a hypersensitivity reaction occurs, perform vital signs every 15 minutes for one hour, then every 30 minutes for 2 hours.			
☒ Nursing communication	PRN		Until discontinued

	Interval	Defer Until	Duration
Once Starting when released If hypersensitivity reaction occurs:			
- Elevate head of bed 30 degrees and place patient's head at 30 degree angle if possible			
- Start 2 liters oxygen per nasal cannula and maintain airway			
- Change and maintain IV line with 1000 mL 0.9% Normal Saline			
☒ sodium chloride 0.9 % infusion	PRN		Until discontinued
30 mL/hr, intravenous, Continuous PRN, KVO, Starting when released, for 1 day			
☒ albuterol 2.5 mg /3 mL (0.083 %) nebulizer solution 2.5 mg	PRN		Until discontinued
2.5 mg, nebulization, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day			
☒ albuterol HFA 90 mcg/act inhaler 2 puff	PRN		Until discontinued
2 puff, inhalation, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day			
SHAKE WELL			
☒ acetaminophen (Tylenol) tablet 650 mg	PRN		Until discontinued
650 mg, oral, Once as needed, fever, GREATER THAN or EQUAL TO 38 C, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
☒ diphenhydramine (BENADryl) injection 25 mg	PRN		Until discontinued
25 mg, intravenous, Administer over: 2 Minutes, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
☒ diphenhydramine (BENADryl) injection 50 mg	PRN		Until discontinued
50 mg, intravenous, Administer over: 2 Minutes, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			
☒ hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	PRN		Until discontinued
100 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
- OR -			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			
☒ EPINEPHrine (EpiPen;Adrenalin) injection solution 0.3 mg	PRN		Until discontinued
0.3 mg, intramuscular, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			

Appointment Requests

☒ Infusion Appointment Request	Every 28 days		3 treatments
Status: Future, Expected: S, Expires: S+365, Sched. Duration: 60 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			
☒ Infusion Appointment Request	Every 56 days	S+112	Until discontinued
Status: Future, Expected: S, Expires: S+365, Sched. Duration: 60 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			

*Provider signature

Provider printed name

*Date

Time

*Provider phone#

***Denotes field that must be completed by healthcare worker**